Most cited papers from Galapagos (Belgium)

Galapagos (Belgium)

What are the most cited papers from Galapagos (Belgium)?

The most cited paper from Galapagos (Belgium) is "Global incidence and prevalence of idiopathic pulmonary fibrosis" (Toby M. Maher, Elisabeth M. Bendstrup, Louis Dron et al., 2021), with 638 citations. Next come "Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial" (457) and "Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial" (441).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 66 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Global incidence and prevalence of idiopathic pulmonary fibrosis Toby M. Maher, Elisabeth M. Bendstrup, Louis Dron et al. · Respiratory Research Open access	7 Jul 2021	638
2	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial Brian G. Feagan et al. · The Lancet	Jun 2021	457
3	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial Severine A.R.A. Vermeire, Stefan Schreiber, Robert Petryka et al. · The Lancet	14 Dec 2016	441
4	Global spatial risk assessment of sharks under the footprint of fisheries Nuno C. Queiroz et al. · Nature Open access153 authors	24 Jul 2019	405
5	Feral Goat Eradications on Islands Karl J. Campbell, C. Josh Donlan · Conservation Biology	6 Sep 2005	346
6	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy Mark C. Genovese, KENNETH C. KALUNIAN, Jacques‐Eric Gottenberg et al. · JAMA Open access	23 Jul 2019	337
7	Alien Insects: Threats and Implications for Conservation of Galápagos Islands Charlotte E. Causton, Stewart B. Peck, Bradley J. Sinclair et al. · Annals of the Entomological Society of America Open access	2006	261
8	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial Désirée M F M van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet Open access	22 Oct 2018	258
9	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial Bernard G Combe, Alan Kivitz, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases Open access	27 Jan 2021	253
10	Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine Open access	20 May 2018	238
11	Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) René Westhovens, Peter Charles Taylor, Rieke Alten et al. · Annals of the Rheumatic Diseases Open access	24 Dec 2016	237
12	Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology Open access	5 Sep 2013	237
13	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) Arthur Kavanaugh, Joel M. Kremer, L Ponce et al. · Annals of the Rheumatic Diseases Open access	24 Dec 2016	234
14	Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson et al. · Journal of Medicinal Chemistry	21 Jan 2014	217
15	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial Philip J. Mease, Laura C. Coates, Philip Helliwell et al. · The Lancet Open access	22 Oct 2018	207
16	The Orphan G Protein–Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons Amantha Thathiah, Kurt Spittaels, Marcel Hoffmann et al. · Science	12 Feb 2009	201
17	Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway Cary W. Esselens, Viola M. J. Oorschot, Veerle Baert et al. · The Journal of Cell Biology Open access	27 Sep 2004	172
18	Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide Ira Espuny-Camacho, Lutgarde Serneels, Kurt Spittaels et al. · Journal of Neuroscience Open access	Dec 2004	170
19	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial René Westhovens, William F. C. Rigby, Désirée M F M van der Heijde et al. · Annals of the Rheumatic Diseases Open access	15 Jan 2021	152
20	Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis Nicolas Desroy et al. · Journal of Medicinal Chemistry Open access	17 Apr 2017	141
21	Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis Toby M. Maher et al. · JAMA Open access252 authors	9 May 2023	140
22	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection Florence Namour, Paul M. Diderichsen, Eugene H. Cox et al. · Clinical Pharmacokinetics Open access	13 Feb 2015	138
23	Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates Olivia Goethals et al. · Nature Open access	15 Mar 2023	136
24	Enhancing Hit Discovery in Virtual Screening through Absolute Protein–Ligand Binding Free-Energy Calculations Wei Chen, Di Cui, Steven V. Jerome et al. · Journal of Chemical Information and Modeling	11 May 2023	129
25	Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634 Christel J. Menet, Stephen Robert Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry Open access	4 Nov 2014	124
26	Plastic contamination of a Galapagos Island (Ecuador) and the relative risks to native marine species Jen Jones, Adam Porter, Juan Pablo Muñoz‐Pérez et al. · The Science of The Total Environment Open access	12 May 2021	120
27	Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis Nick Vandeghinste, Jürgen Klattig, Catherine Jagerschmidt et al. · Journal of Investigative Dermatology Open access	21 Feb 2018	118
28	The Hedgehog Receptor Patched Is Involved in Cholesterol Transport Michel Bidet, Olivier Joubert, Benoı̂t Lacombe et al. · PLoS ONE Open access	8 Sep 2011	117
29	A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIβ Hilde M. van der Schaar, Pieter Leyssen, Hendrik Jan Thibaut et al. · Antimicrobial Agents and Chemotherapy Open access	29 Jul 2013	116
30	The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome Erik Verschueren, Bushra Husain, Kobe Chi Yung Yuen et al. · Cell Open access	25 Jun 2020	115
31	Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic Mathieu Pizzonero et al. · Journal of Medicinal Chemistry Open access	7 Nov 2014	114
32	Fungal Planet description sheets: 1478–1549 Pedro Willem Crous et al. · Persoonia - Molecular Phylogeny and Evolution of Fungi Open access146 authors	29 Jun 2023	111
33	Presenilins Mutated at Asp-257 or Asp-385 Restore Pen-2 Expression and Nicastrin Glycosylation but Remain Catalytically Inactive in the Absence of Wild Type Presenilin Omar Nyabi, Mostafa Bentahir, Katrien Horré et al. · Journal of Biological Chemistry Open access	Oct 2003	111
34	Predicting Pathogen Introduction: West Nile Virus Spread to Galápagos Auston Marm Kilpatrick, Peter Daszak, Simon J. Goodman et al. · Conservation Biology	24 Apr 2006	109
35	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) Toby M. Maher, Michael Kreuter, David J. Lederer et al. · BMJ Open Respiratory Research Open access	May 2019	102
36	Inter-island movements of scalloped hammerhead sharks (Sphyrna lewini) and seasonal connectivity in a marine protected area of the eastern tropical Pacific James Thomas Ketchum, Alex R. Hearn, Abbott Peter Klimley et al. · Marine Biology	28 Jan 2014	101
37	Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design Javier Blanc, Raphaël Geney, Christel J. Menet · Anti-Cancer Agents in Medicinal Chemistry	May 2013	99
38	Diving into the vertical dimension of elasmobranch movement ecology Samantha Andrzejaczek et al. · Science Advances Open access171 authors	19 Aug 2022	93
39	The gut of the finch: uniqueness of the gut microbiome of the Galápagos vampire finch Alice Michel, Lewis M. Ward, Shana K. Goffredi et al. · Microbiome Open access	19 Sep 2018	93
40	Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene Function Gert‐Jan Arts, Ellen Langemeijer, Rudi Tissingh et al. · Genome Research Open access	2003	93
41	On the Biology of Tropidurus delanonis, Baur (Iguanidae) Dagmar I. Werner · Zeitschrift für Tierpsychologie	12 Jan 1978	90
42	The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis Tobias Puengel, Steve De Vos, Jana Hundertmark et al. · Journal of Clinical Medicine Open access	16 Apr 2020	87
43	Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis Niklas Jonathan Lang et al. · Science Translational Medicine	6 Dec 2023	85
44	The α7 nicotinic acetylcholine receptor on fibroblast‐like synoviocytes and in synovial tissue from rheumatoid arthritis patients: A possible role for a key neurotransmitter in synovial inflammation Marjolein A. van Maanen, Susanne P. Stoof, Esmerij P. van der Zanden et al. · Arthritis & Rheumatism	29 Apr 2009	85
45	A multiparameter approach to monitor disease activity in collagen-induced arthritis Sylvie Seeuws, Peggy Jacques, Jens Tomas Van Praet et al. · Arthritis Research & Therapy Open access	23 Aug 2010	85
46	Arrayed adenoviral expression libraries for functional screening Frits Michiels et al. · Nature Biotechnology	30 Sep 2002	84
47	Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials Frédéric P. Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology Open access	16 Jun 2017	82
48	Can We Infer Island Introduction and Naturalization Rates from Inventory Data? Evidence from Introduced Plants in Galapagos Alan Tye · Biological Invasions	30 Dec 2005	80
49	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate Ramon Roozendaal et al. · npj Vaccines Open access	17 Dec 2020	79
50	Seasonal changes in movements and habitat preferences of the scalloped hammerhead shark (Sphyrna lewini) while refuging near an oceanic island James Thomas Ketchum, Alex R. Hearn, Abbott Peter Klimley et al. · Marine Biology	7 Jan 2014	79

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.